Hemophilia
Hemophilia
Advertisement
Andrew MorenoHemophilia | June 27, 2024
Quality of life improvement is among the benefits from this agent in patients with congenital disease.
Read More
Andrew MorenoHemophilia | June 18, 2024
A retrospective observational study's clearest takeaway was that the agent can reduce spontaneous bleeding in severe disease.
Andrew MorenoHemophilia | May 29, 2024
These proof-of-concept data may spur further studies toward developing a single-intervention cure for patients.
Leah LawrenceHemophilia | May 21, 2024
Patients with hemophilia A who received prophylaxis had a reduced risk for ICH.
Leah LawrenceHemophilia | May 14, 2024
Analysis shows pharmacokinetic-guided dosing may be effective for guiding prophylactic factor concentrate therapy.
Leah LawrenceHemophilia | May 14, 2024
Compared with before surgery, the percentage of factor VIII increase was 42.9% at day one and 36.4% on day two.
Leah LawrenceHemophilia | May 10, 2024
Free tissue factor pathway inhibitor levels were associated with thrombin generation in patients with severe hemophilia.
Patrick DalyHemophilia | April 29, 2024
The US FDA has approved fidanacogene elaparvovec-dzkt, a gene therapy for adults with hemophilia B.
Erica Mamauag, MDHemophilia | April 9, 2024
Dr. Mamauag details her study on the need for factor VIII infusions in patients with tolerized hemophilia A on emicizumab.
Patrick DalyHemophilia | April 1, 2024
The US FDA has approved an expanded indication for IXINITY to control bleeding in all patients with hemophilia B.
Patrick DalyHemophilia | February 21, 2024
Desmopressin with FVIII during operations was reportedly feasible and safe in patients with nonsevere hemophilia A.
Patrick DalyHemophilia | February 14, 2024
Patients with hemophilia A or B had low rates of VTE after total joint replacement despite infrequent thromboprophylaxis use.
Patrick DalyHemophilia | February 8, 2024
Desmopressin was safe and effective for women with inherited bleeding disorders during both pregnancy and delivery.
Patrick DalyHemophilia | January 12, 2024
Health Canada approved fidanacogene elaparvovec, an adenoviral vector-based gene therapy for patients with hemophilia B.
Patrick DalyHemophilia | January 19, 2024
The FDA and EMA are expected to make decisions on once-weekly subcutaneous marstacimab for patients with hemophilia A or B.
Patrick DalyHemophilia | December 14, 2023
Large deletions in the FVIII gene (F8) were shown to be predictors of ITI therapy failure.
Patrick DalyHemophilia | December 14, 2023
Emicizumab plus ITI did not induce new safety signals in patients with hemophilia A.
Patrick DalyHemophilia | December 14, 2023
A single infusion of AAV-HLP-hFVIII-V3 induced stable FVIII expression over five years.
Patrick DalyHemophilia | December 14, 2023
Women with inherited bleeding disorders may need prophylaxis.
Patrick DalyHemophilia | December 14, 2023
First patient treated with hemophilia A gene therapy demonstrates "promising" outcomes.
Advertisement
Advertisement
Advertisement
Latest News

July 12, 2024